Takeaways:
- Young adults and adolescents are most likely to discontinue ADHD medication within 5 years.
- Reasons for discontinuation include adverse events, lack of understanding about medication benefits, improper dosing, and insurance coverage issues.
- The study, spanning multiple countries, included 1,229,972 individuals aged 3 years and older who started ADHD medication between 2010 – 2020.
- Within a year of starting medication, rates of continuation were 65% for children, 47% for adolescents, 39% for young adults, and 48% for adults.
- Young adults aged 18 – 19 had the highest discontinuation rates, and reinitiation of medication was common across age groups.
A recent study reveals that young adults and adolescents are the age groups with the highest likelihood of discontinuing ADHD medication within 5 years.1
Discontinuation of ADHD medication is common. Patients may discontinue their ADHD medication due to unpleasant adverse events like decreased appetite, headaches, sleepiness, irritability, anxiety, insomnia, or mood changes.2 About 80% of people who take stimulant ADHD medication experience decreased appetite.3 Other side effects can include making already present tics more noticeable, minor growth delay, upset stomach, and changes in blood pressure and heart rate. Or they may discontinue for other reasons—not understanding how medication helps ADHD, improper dosing, the medication not improving symptoms, and lack of insurance coverage.2
Meanwhile, discontinuing ADHD medication can cause a patient to become more fatigued during the day and to become extremely hungry. Energy levels often return to normal in a few days, but it could take a few weeks for appetite to return to normal.
Due to the lack of cross-national estimates of discontinuation, a new study wanted to determine the rate of ADHD medication discontinuation across the lifespan.1 Led by Isabell Brikell, PhD, from the department of global public health and primary care at University of Bergen in Bergen, Norway; the department of medical epidemiology and biostatistics at Karolinska Institutet in Stockholm, Sweden; and the department of biomedicine at Aarhus University from Aarhus, Denmark, the new retrospective, observational study pulled data from population-based databases. Databases came from Australia, Denmark, Hong Kong, Iceland, the Netherlands, Norway, Sweden, United Kingdom, and the United States.